Genetic profiling has demonstrated these mutations in small cell carcinoma of the ovary and hypercalcemic type (SCCOHT) and SMARCA4-deficient undifferentiated uterine sarcoma, as well as atypical teratoid rhabdoid tumors, malignant rhabdoid tumors, and aggressive SMARCA4-deficient thoracic sarcomas [148, 149]. This evidence concerns the gene SMARCA4 and ovarian small cell carcinoma.